尽管第四季度的业绩好于预期,但生物的股价下跌,因为2025年前景远远超出预期. Biogen's stock dropped despite better-than-expected Q4 results, as 2025 outlook missed expectations.

在几家金融公司降低评级和降低价格目标之后,生物基因的股票下跌。 Biogen's stock fell after several financial firms downgraded their ratings and lowered price targets. 尽管比预期的Q4收入和利润有所改善,但Biogen的2025年展望没有达到预期,预测每股调整利润在15.25至16.25美元之间,预计收入将下降中位数。 Despite reporting better-than-expected Q4 revenue and profit, Biogen's 2025 outlook missed expectations, with forecasted adjusted profit between $15.25 and $16.25 per share, and revenue expected to decline by a mid-single-digit percentage. 预计该公司新的阿尔茨海默氏病治疗方法Leqembi将有助于抵消其他产品的下降。 The company's new Alzheimer's treatment, Leqembi, is expected to help offset declines in other products.